How Sapropterin Works in PKU
Sapropterin, also known as Kuvan or tetrahydrobiopterin (BH4), acts as a synthetic form of the natural cofactor BH4. In phenylketonuria (PKU), genetic mutations impair the enzyme phenylalanine hydroxylase (PAH), which normally converts phenylalanine (Phe) to tyrosine using BH4 as a cofactor. This leads to toxic Phe buildup in blood and brain.
Sapropterin boosts residual PAH activity in responsive patients—about 20-30% of those with mild or moderate PKU—lowering blood Phe levels without fully relying on a strict low-Phe diet.[1]
Why Only Some PKU Patients Respond
Responsiveness depends on PAH mutation type. Patients with mutations allowing partial enzyme function (e.g., certain missense variants) see BH4 stabilize and enhance PAH, restoring cofactor binding. Non-responders have severe defects like PAH misfolding or complete loss, unaffected by extra BH4. A BH4 loading test (high-dose sapropterin for 24-48 hours) predicts response: ≥30% Phe drop qualifies treatment.[2]
Mechanism Step-by-Step
1. Sapropterin enters cells and regenerates BH4.
2. BH4 binds PAH, promoting its dimer-tetramer assembly for activity.
3. Active PAH hydroxylates Phe to tyrosine, reducing hyperphenylalaninemia.
4. Unlike natural BH4 (quickly oxidized), sapropterin is orally stable and recycled via dihydrofolate reductase.
This chaperone-like effect can increase PAH activity up to 4-fold in vitro.[3]
Dosing and Expected Phe Reduction
Typical dose: 10 mg/kg/day orally, sometimes up to 20 mg/kg. Responders often cut Phe 25-50% within weeks, allowing relaxed diet. Non-responders see no change.[1]
Limitations and Who It Helps Most
Works best in early-onset or mild PKU (Phe 360-1200 μmol/L at diagnosis). Ineffective for classic PKU (Phe >1200 μmol/L). Long-term use maintains gains but requires monitoring for tolerance loss. Not a cure—combines with diet.[2]
Alternatives if Sapropterin Fails
- Strict Phe-restricted diet (primary for all PKU).
- Large neutral amino acids (LNAA) to block Phe brain uptake.
- Emerging: Pegvaliase (Palynziq), an enzyme substitute for adults, injects Phe-oxidizing enzyme outside cells.[4]
Sources
[1]: FDA Label for Kuvan
[2]: New England Journal of Medicine Review on BH4 Therapy
[3]: Biochemical Pharmacology on PAH-BH4 Interaction
[4]: FDA Approval Summary for Palynziq